Boyu Capital Leads $120M Series B Round Into Oncology Medicine Developer Antengene

Login to View

Antengene Corporation, a Chinese clinical-stage therapeutics company focused on oncology, has secured a US$120 million in series B round of financing, jointly led by Boyu Capital and FountainVest, according to a statement released today.

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in